Orthofix Medical stock (US6875231068): Brokerages rate Hold with $17.25 target

Orthofix Medical (NASDAQ:OFIX) carries a consensus Hold rating from six brokerages, with an average 12-month price target of $17.25, per recent analyst updates.

Orthofix Medical Inc. has received an average rating of Hold from six covering brokerages, accompanied by a 12-month price target of $17.25, according to data compiled as of May 14, 2026 by MarketBeat as of 05/14/2026. This consensus reflects the latest analyst views on the medical device company's outlook amid its focus on spine and orthopedics solutions.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Orthofix Medical Inc
• Sector/industry: Medical Devices
• Headquarters/country: United States
• Core markets: Spine and orthopedics
• Home exchange/listing venue: Nasdaq (OFIX)
• Trading currency: USD

Orthofix Medical: core business model

Orthofix Medical develops and delivers innovative medical technologies for spine and orthopedic conditions. The company offers a portfolio including bone growth stimulation devices, spinal fixation systems, and non-surgical orthopedic solutions. These products target clinicians treating complex spinal disorders and extremity fractures, with a focus on minimally invasive and patient-centric therapies.

Headquartered in the US, Orthofix operates globally but maintains significant exposure to the American healthcare market, where demand for advanced musculoskeletal treatments drives growth. Its business model emphasizes research-driven innovation and partnerships with healthcare providers to improve patient outcomes in orthopedics.

Main revenue and product drivers for Orthofix Medical

Key revenue streams for Orthofix Medical stem from its BioStim and Spinal Implants segments. BioStim products, such as the CervicalStim and Limb Reconstruction Systems, generated substantial sales in recent periods by promoting bone healing without surgery. Spinal Implants contribute through systems like the Ascension and Firebird devices used in fusion procedures.

The company's US-centric revenue, reported at over 80% in prior filings, underscores its relevance to American investors tracking medtech growth amid rising orthopedic procedure volumes. Orthofix also derives income from extremity fixation and regenerative biologics, bolstering its position in the competitive medical device landscape.

Industry trends and competitive position

The orthopedic device sector is expanding due to aging populations and advances in biologics, with US market projections showing steady demand per sector reports. Orthofix differentiates through specialized spine technologies amid competition from larger peers like Medtronic and Globus Medical. Its focus on non-fusion alternatives positions it well for shifts toward less invasive treatments.

Why Orthofix Medical matters for US investors

Listed on Nasdaq, Orthofix Medical offers US investors direct access to a pure-play medtech firm with heavy reliance on the domestic healthcare system. Exposure to Medicare reimbursements and elective procedure recovery post-pandemic enhances its appeal in portfolios seeking orthopedic innovation amid broader US economic resilience.

Conclusion

Orthofix Medical maintains a Hold consensus from analysts, reflecting balanced views on its medtech portfolio amid sector tailwinds. With a $17.25 average target and Nasdaq listing, the stock tracks orthopedic demand relevant to US portfolios. Investors monitor upcoming catalysts like product launches for further developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.